Doctors Want More Ebola Cases, Here's Why

By Admin
The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the diseas...

The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the disease, as it will be more difficult to recruit study participants and demonstrate efficacy, says an analyst with research and consulting firm GlobalData.

According to Daian Cheng, Ph.D., GlobalData’s Analyst covering Infectious Diseases, Ebola’s dwindling incidence rate is having a direct impact on patient enrollment for clinical trials of therapeutic agents, as evidenced by two studies for antiviral drugs favipiravir and brincidofovir.

[READ MORE] This Ebola Outbreak Might Not Go Away For A Very Long Time

“On January 30, Chimerix announced the decision to cease clinical investigations of its experimental Ebola drug, brincidofovir, as only a handful of participants were able to be recruited for a single-armed clinical trial in Liberia,” said Cheng. “The disease’s decreasing incidence meant the study was unlikely to reach a convincing conclusion regarding the drug’s efficacy.”

In contrast, the analyst highlights the early success of anti-influenza drug, favipiravir (Avigan), in a clinical trial in Guinea. This product, currently marketed in Japan by FujiFilm Holdings Corporation, produced positive initial results, which encouraged the Guinea government to approve its use in a limited number of Ebola treatment centers.

[READ MORE] Scared of Ebola? This Measles Outbreak is Far More Dangerous.

“The favipiravir trial was not hindered by low patient recruitment, possibly due to its earlier start date compared with the brincidofovir trial,” Cheng added. “The fact that Guinea’s local incidence rate was higher than Liberia’s might also have contributed to its outcome. The information available from favipiravir’s trial indicated that the drug could lower mortality rates and accelerate recovery in patients with low or moderate levels of Ebola virus in their blood. However, in the face of diminishing cases, its future use is uncertain.”

Cheng adds that for pharmaceutical companies, the use of established antiviral agents certainly has its advantages, especially if a treatment can be positioned as an option for relieving an outbreak while still being useful and profitable for other indications when the outbreak subsides.

“Overall, Ebola’s current decline means vaccine and drug manufacturers will again need to weigh the risks and benefits of developing further interventions for a disease that goes through unpredictable cycles of intense outbreaks followed by its virtual disappearance,” Cheng concluded.

Follow us on Twitter (@HealthcareGlbl) and like us on Facebook!

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals